Stryker

Stryker Corporation (SYK) (Q4FY23) – Exceeding expectations with sustainable growth

Highlights of the report

A robust product pipeline and commitment to innovation position Stryker for continued growth and market leadership. The upcoming launches of MAKO Spine, MAKO Shoulder, and CO-PILOT demonstrate the company’s ability to expand its robotic-assisted surgery offerings and strengthen its position in the spinal and neurosurgery markets.

Stryker Corporation (SYK) Equity Report Q4FY23

CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

 

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

 

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine.

SYK’s revenue has increased by 12% to $4.45bn in Q4FY23 from $5.81bn in Q4FY22. 

Stryker Corporation stock price showed an upward trend in the past 3-month period and gave a 12.2% return. The stock price reduced by -12.56% in the past 1-year. The stock has a 52-week high of $23.35 and a 52-week low of $13.53.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Metrics
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

Report details

Stryker Corporation (SYK) (Q4FY23) – Exceeding expectations with sustainable growth

Price

$304.00

Company Reports

Sector Reports